LUNA MEDICAL TECHNOLOGIES INC
10QSB, EX-27, 2000-08-21
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: LUNA MEDICAL TECHNOLOGIES INC, 10QSB, 2000-08-21
Next: TRIMFAST GROUP INC, 10QSB, 2000-08-21



<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
This schedule contains summary financial information extracted from the
unaudited Consolidated Balance Sheet as at June 30, 2000 and the unaudited
Consolidated Statement of Operations and Comprehensive Income for the three
month period ended June 30, 2000 and is qualified in its entirety by reference
to such financial statements.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                              MAR-31-2000
<PERIOD-END>                                   JUN-30-2000
<CASH>                                                2951
<SECURITIES>                                             0
<RECEIVABLES>                                         1751
<ALLOWANCES>                                        (1348)
<INVENTORY>                                            312
<CURRENT-ASSETS>                                    21,653
<PP&E>                                                2543
<DEPRECIATION>                                       (424)
<TOTAL-ASSETS>                                       26231
<CURRENT-LIABILITIES>                               259721
<BONDS>                                                  0
                                    0
                                              0
<COMMON>                                              8096
<OTHER-SE>                                        (241586)
<TOTAL-LIABILITY-AND-EQUITY>                      (233490)
<SALES>                                               5261
<TOTAL-REVENUES>                                      5261
<CGS>                                                 4341
<TOTAL-COSTS>                                         4341
<OTHER-EXPENSES>                                    237282
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                      62
<INCOME-PRETAX>                                   (236137)
<INCOME-TAX>                                             0
<INCOME-CONTINUING>                               (236137)
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                      (236137)
<EPS-BASIC>                                         (0.03)
<EPS-DILUTED>                                       (0.03)



</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission